Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

First Warning Letter Issued Under DSCSA

FDA sends McKesson a warning, highlighting issues with illegitimate product notification, quarantining and record-keeping.

On Feb. 7, 2019, the FDA issued its first warning letter for verification requirements violations post-DSCSA enforcement date.

 

According to the letter to McKesson, “The verification requirements at issue include those that apply to wholesale distributors when they determine or are notified that a product is suspect or illegitimate.”

 

The letter comes after a Form 483 was issued to the company back in July 2018. The FDA notes that the firm failed to respond to illegitimate product notifications as required, quarantine and investigate suspect product and keep records of the investigation of suspect product (for no less than 6 years).

Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?